Author(s): Mansimran Kaur Randhawa ,*, Aruna Bhatia and Praveen Pal Balgir
The recent increase in the incidence of diabetes raises a need to find new alternative therapies to control it. Probiotics reduces the blood glucose concentrations .But recently bacterial DNA is also being explored as an immune enhancer. Present study was conducted to compare the in vivo antidiabetic capacity of three probiotic strains as live bacteria with their genomic DNA. Probiotic bacteria’s (109 cells ml-1) were administered orally to swiss albino mice whereas their extracted DNA’s (75 μg mL-1) were injected into the tibialis anterior muscle. Experiment involved the acute study (24 h) and sub-acute study (28 days). Standard drug Glyburide (10 mg/kg b.wt) was given alone and also in combination with probiotic and with their genomic DNA. Oral glucose tolerance test (OGTT) in normal and diabetic mice was also tested in vivo. The blood samples so collected were analyzed for blood glucose levels. The combination of standard drug (glyburide) and DNA of probiotics exerted an antihyperglycemic effect and showed better reduction in glucose levels than glyburide alone. However, probiotic bacteria showed only 2.71 % decrease in glucose level in comparison to DNA which showed 16.7 % decrease. It is concluded that genomic DNA of probiotics should be exploited as a potent antihyperglycemic biotherapeutic agent.